Novel Methods for Assessing Oral Direct Factor Xa and Thrombin Inhibitors: Use of Point-Of-Care Testing and Urine Samples

Seminars in Thrombosis and Hemostasis - United States
doi 10.1055/s-0032-1331155
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Georg Thieme Verlag KG

Related search

Antithrombin-Independent Thrombin Inhibitors, but Not Direct Factor Xa Inhibitors, Enhance Thrombin Generation in Plasma Through Inhibition of Thrombin-Thrombomodulin-Protein C System

Thrombosis and Haemostasis
Hematology
2011English

Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa Inhibitors

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2017English

Rivaroxaban: An Oral Direct Inhibitor of Factor Xa

American Journal of Health-System Pharmacy
MedicineHealth PolicyPharmacologyPharmacy
2008English

The Pointy End of Point-Of-Care Testing for Direct Oral Anticoagulants

Thrombosis and Haemostasis
Hematology
2019English

Factor Xa Inhibitors

2016English

Discovery of a Novel, Potent, and Specific Family of Factor Xa Inhibitors via Combinatorial Chemistry

Biochemistry
Biochemistry
1998English

Effect of Famotidine on the Pharmacokinetics of Apixaban, an Oral Direct Factor Xa Inhibitor

Clinical Pharmacology: Advances and Applications
Pharmacology
2013English

Safety, Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor – In Elderly Chinese Subjects

Thrombosis and Haemostasis
Hematology
2010English

Antithrombotic Drug and Its Clinical Indication. Factor Xa Inhibitor. Oral Xa Inhibitor (DX-9065a).

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
1996English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy